EBOS delivers solid FY25 results, targets further growth in FY226

EBOS Group reported underlying revenue growth of 12.0% to $12.3 billion and underlying EBITDA of $585 million, an increase of 7.5% over FY24. The EBITDA result falls within the company's guidance range of $575 million to $600 million. The group generated strong underlying free cash flow of $302 million, with a cash realisation of 109%.

The healthcare segment's revenue reached $11.6 billion, with underlying EBITDA of $500 million, increasing by 11.8% and 6.9% respectively. Animal care also contributed significantly, with revenue of $673 million and underlying EBITDA of $124 million, representing growth of 16.3% and 10.4% respectively. EBOS also completed five acquisitions, primarily in medical technology and animal care, costing approximately $210 million.

For FY26, EBOS is targeting underlying EBITDA between $615 million and $635 million, reflecting approximately 7% midpoint growth. The company declared a final dividend of NZ 61.5 cents per share, maintaining the dividend at the same level as FY24.